Quintiles IMS Holdings Inc.

• May. 20, 2017 at 1:22 a.m. ET
• on Barron's Online

Private-equity firms and other investors are funding late-stage clinical trials, shouldering the risk for pharmaceutical companies like Pfizer in exchange for a share of the upside if a drug succeeds.

• Apr. 30, 2017 at 9:00 a.m. ET
• on The Wall Street Journal

Quintiles IMS Holdings Inc. aims to provide its clinical-trial and prescription-drug data through the cloud-based technology developed by Salesforce.com.

• Apr. 24, 2017 at 5:30 a.m. ET
• on The Wall Street Journal